KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Change in Acquisitions & Divestments (2023 - 2025)

Castle Biosciences' Change in Acquisitions & Divestments history spans 3 years, with the latest figure at -$133.7 million for Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments fell 8.45% year-over-year to -$133.7 million; the TTM value through Dec 2025 reached $1.5 million, changed N/A, while the annual FY2025 figure was $1.5 million, N/A changed from the prior year.
  • Change in Acquisitions & Divestments for Q4 2025 was -$133.7 million at Castle Biosciences, down from $54.9 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $54.9 million in Q3 2025 and bottomed at -$138.0 million in Q4 2023.
  • The 3-year median for Change in Acquisitions & Divestments is $39.9 million (2023), against an average of $127750.0.
  • The largest YoY upside for Change in Acquisitions & Divestments was 49.18% in 2025 against a maximum downside of 27.69% in 2025.
  • A 3-year view of Change in Acquisitions & Divestments shows it stood at -$138.0 million in 2023, then rose by 10.69% to -$123.2 million in 2024, then fell by 8.45% to -$133.7 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Change in Acquisitions & Divestments are -$133.7 million (Q4 2025), $54.9 million (Q3 2025), and $44.0 million (Q2 2025).